Navigation Links
Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis

OWL Genomics, biotechnological company, has presented at the CIC bioGUNE hold at the Bizkaia Technological Park (Derio), the first DNA chip concerning diagnosis and prognosis of non-alcoholic steatohepatitis (NASH), allowing the discrimination between normal, steatosis and NASH predisposed subjects.

Non alcoholic steatohepatitis is a progressive disease of the liver of unknown etiology, characterized histologically by fatty acid accumulation, hepatocyte damage and inflammation resembling alcoholic hepatitis. NASH is a critical stage in the process that spans from hepatic steatosis to cirrhosis and hepatocarcinoma. NASH is one of the most common causes of elevated aminotransfereases in patients referred for evaluation to hepatologists. Obesity and type-2 diabetes are associated to NASH. Since the prevalence of these diseases is increasing, the prevalence of NASH is also expected to increase and therefore, this disease has become an emerging public issue in United States as well as in other developed countries

The HEPATOCHIP presented at the mentioned forum, has been developed in collaboration with the Hepatology Services of the Clinic Hospital in Barcelona and Príncipe de Asturias Hospital in Alcalá de Henares (Madrid). This chip analyses the co-expression of 85 genes that are related with NASH and is about to be validated in collaboration with the Hepatology Service of Gregorio Marañón Hospital (Madrid).

This HEPATOCHIP method determines the co-expression of genes in the liver tissue sample, providing monitoring treatment regimens to check progression/regression of these liver pathologies.

This HEPATOCHIP can be used as a prognostic tool for NASH-predisposed patients, to make possible more finely tuned diagnosis of this disease and allow healthcare professionals to tailor treatment to individual patients' needs. This chip also assess the efficacy of non-alcoholic steatohepatitis treatment by determining progression or regression of NAS H in patients before, during, and NASH treatment.


OWL Genomics, a biotech company focused on providing leading-edge applications in human health with innovative and pioneer technologies within the international scientific community, provides the first product in early diagnosis and therapeutic targets in hepatic diseases.

OWL Genomics is devoted to research into the diagnosis and prevention of liver diseases, through the combination of its state-of-the-art technology and experienced and dedicated personnel.



Related biology news :

1. New comparative toxicogenomics database
2. Measuring the impact of post-genomics on Mediterranean populations
3. Enlisting genomics to understand flu evolution
4. Drawing with DNA: Bioart illuminates genomics
5. Study reveals genomics of inflammation from severe injury
6. NIH launches comprehensive effort to explore cancer genomics
7. Environmental metagenomics diagnosing extreme environments, tapping opportunities for clean energy
8. Ticks, flukes, and genomics: Emerging pathogens revealed
9. UC San Diego partners with Venter Institute to build marine microbial genomics cyberinfrastructure
10. Advanced genomics and proteomics improve the diagnosis and treatment of a deadly lung disease
11. Large-scale genomics project will hunt genes behind common childhood diseases
Post Your Comments:

(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division of ... and optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology ... among several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, ...
Breaking Biology Technology: